tranexamic acid has been researched along with Joint Diseases in 11 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Joint Diseases: Diseases involving the JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid (TXA) has been used to reduce blood loss during total hip arthroplasty (THA), but its use could increase the risk of venous thromboembolic disease (VTE)." | 5.42 | Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? ( Hamada, M; Nishihara, S, 2015) |
| "Tranexamic acid (TXA) is an efficient antifibrinolytic agent, but the mode and timing of its administration remain controversial." | 2.90 | A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty. ( Baynat, C; Clavé, A; Danguy des Déserts, M; Gatineau, F; Gérard, R; Lacroix, J; Mottier, D, 2019) |
| "Tranexamic acid (TXA) has been used to reduce blood loss during total hip arthroplasty (THA), but its use could increase the risk of venous thromboembolic disease (VTE)." | 1.42 | Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? ( Hamada, M; Nishihara, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, B | 1 |
| Zhang, W | 1 |
| Xu, J | 1 |
| Ding, J | 1 |
| Boese, CK | 1 |
| Centeno, L | 1 |
| Walters, RW | 1 |
| Clavé, A | 1 |
| Gérard, R | 1 |
| Lacroix, J | 1 |
| Baynat, C | 1 |
| Danguy des Déserts, M | 1 |
| Gatineau, F | 1 |
| Mottier, D | 1 |
| Sandri, A | 1 |
| Mimor, BF | 1 |
| Ditta, A | 1 |
| Finocchio, E | 1 |
| Danzi, V | 1 |
| Piccoli, P | 1 |
| Regis, D | 1 |
| Magnan, B | 1 |
| Concina, C | 1 |
| Crucil, M | 1 |
| Fabbro, S | 1 |
| Gherlinzoni, F | 1 |
| Meftah, M | 1 |
| White, PB | 1 |
| Siddiqi, A | 1 |
| Siddappa, VH | 1 |
| Kirschenbaum, I | 1 |
| Basora, M | 1 |
| Tió, M | 1 |
| Martin, N | 1 |
| Lozano, L | 1 |
| Salazar, F | 1 |
| Sánchez-Etayo, G | 1 |
| Raquel, B | 1 |
| Pereira, A | 1 |
| Nishihara, S | 1 |
| Hamada, M | 1 |
| Goyal, N | 1 |
| Chen, DB | 1 |
| Harris, IA | 1 |
| Rowden, N | 1 |
| Kirsh, G | 1 |
| MacDessi, SJ | 1 |
| Rodriguez-Merchan, EC | 1 |
| Romero-Garrido, JA | 1 |
| Gomez-Cardero, P | 1 |
| Epis, O | 1 |
| Caporali, R | 1 |
| Scirè, CA | 1 |
| Bruschi, E | 1 |
| Bonacci, E | 1 |
| Montecucco, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.[NCT03365999] | Phase 2 | 92 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 1 |
| Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 0 |
| Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | ml (Mean) |
|---|---|
| Combined Topical TXA and Floseal | 678 |
| Topical TXA Alone | 733 |
4 trials available for tranexamic acid and Joint Diseases
| Article | Year |
|---|---|
Effect of topical tranexamic acid on post-traumatic elbow stiffness in patients treated with open arthrolysis: a prospective comparative study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Drainage; Elbow; Elbow Joint; Female; Humans; | 2020 |
Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid After Total Knee Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2017 |
A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2019 |
Efficacy of tidal irrigation in Milwaukee shoulder syndrome.
Topics: Calcium Phosphates; Chondrocalcinosis; Combined Modality Therapy; Crystallization; Drug Therapy, Com | 2007 |
7 other studies available for tranexamic acid and Joint Diseases
| Article | Year |
|---|---|
Perioperative intravenous tranexamic acid reduces blood transfusion in primary cementless total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2019 |
Do tourniquet and drainage influence fast track in total knee arthroplasty? Our results on 151 cases.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2019 |
Tranexamic Acid Reduces Transfusion Rates in Obese Patients Undergoing Total Joint Arthroplasty.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement; Blood Loss, Surgica | 2019 |
Should all patients be optimized to the same preoperative hemoglobin level to avoid transfusion in primary knee arthroplasty?
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Tran | 2014 |
Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis?
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Case-Control Studies; Female; Hip Joi | 2015 |
Clinical and financial benefits of intra-articular tranexamic acid in total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Cost Savings; Fem | 2016 |
Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies | 2016 |